|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US5981216A
(en)
|
1985-04-01 |
1999-11-09 |
Alusuisse Holdings A.G. |
Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
GB8717430D0
(en)
|
1987-07-23 |
1987-08-26 |
Celltech Ltd |
Recombinant dna product
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
HU215581B
(hu)
|
1989-07-06 |
1999-01-28 |
Regents Of The University Of California |
Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására
|
|
US6713610B1
(en)
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5863888A
(en)
|
1990-07-06 |
1999-01-26 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Human Bek Fibroblast growth factor receptor
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
GB9603256D0
(en)
|
1996-02-16 |
1996-04-17 |
Wellcome Found |
Antibodies
|
|
WO1997048813A2
(en)
|
1996-06-18 |
1997-12-24 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Fibroblast growth factor receptor activating gene 1 (frag1). fgfr2-frag1 fusions
|
|
ES2244066T3
(es)
|
1997-06-24 |
2005-12-01 |
Genentech, Inc. |
Procedimiento y composiciones de glicoproteinas galactosiladas.
|
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
|
AU759779B2
(en)
|
1997-10-31 |
2003-05-01 |
Genentech Inc. |
Methods and compositions comprising glycoprotein glycoforms
|
|
DK1034298T3
(da)
|
1997-12-05 |
2012-01-30 |
Scripps Research Inst |
Humanisering af murint antistof
|
|
DK1071700T3
(da)
|
1998-04-20 |
2010-06-07 |
Glycart Biotechnology Ag |
Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
CA2704600C
(en)
|
1999-04-09 |
2016-10-25 |
Kyowa Kirin Co., Ltd. |
A method for producing antibodies with increased adcc activity
|
|
US6342219B1
(en)
|
1999-04-28 |
2002-01-29 |
Board Of Regents, The University Of Texas System |
Antibody compositions for selectively inhibiting VEGF
|
|
EP1229125A4
(en)
|
1999-10-19 |
2005-06-01 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING A POLYPEPTIDE
|
|
JP2001302699A
(ja)
|
2000-04-17 |
2001-10-31 |
Nichirei Corp |
ヒトｋｇｆｒに対する抗体
|
|
CA2953239A1
(en)
|
2000-10-06 |
2002-04-18 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody composition-producing cell
|
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
|
US7064191B2
(en)
|
2000-10-06 |
2006-06-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Process for purifying antibody
|
|
CA2450793A1
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
NZ571596A
(en)
|
2001-08-03 |
2010-11-26 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US20040093621A1
(en)
|
2001-12-25 |
2004-05-13 |
Kyowa Hakko Kogyo Co., Ltd |
Antibody composition which specifically binds to CD20
|
|
EP1469878B1
(en)
|
2002-01-31 |
2011-03-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Fgfr agonists
|
|
AU2003210060B2
(en)
|
2002-03-22 |
2010-02-25 |
Aprogen, Inc. |
Humanized antibody and process for preparing same
|
|
CA2481925A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Therapeutic agent for patients having human fc.gamma.riiia
|
|
EP1500400A4
(en)
|
2002-04-09 |
2006-10-11 |
Kyowa Hakko Kogyo Kk |
MEDICAMENT WITH ANTIBODY COMPOSITION
|
|
ATE503829T1
(de)
|
2002-04-09 |
2011-04-15 |
Kyowa Hakko Kirin Co Ltd |
Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
|
|
CA2481658A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to fcy receptor iiia
|
|
BR0309145A
(pt)
|
2002-04-09 |
2005-02-01 |
Kyowa Hakko Kogyo Kk |
Células das quais o genoma é modificado
|
|
EP1498490A4
(en)
|
2002-04-09 |
2006-11-29 |
Kyowa Hakko Kogyo Kk |
PROCESS FOR PREPARING ANTIBODY COMPOSITION
|
|
KR100493460B1
(ko)
|
2002-08-29 |
2005-06-07 |
재단법인서울대학교산학협력재단 |
암 세포에서 발현되는 ｆｇｆｒ2 이성체
|
|
TWI335821B
(en)
|
2002-12-16 |
2011-01-11 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
|
JPWO2005035586A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
融合蛋白質組成物
|
|
JPWO2005035778A1
(ja)
|
2003-10-09 |
2006-12-21 |
協和醗酵工業株式会社 |
α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
|
|
EP2060270A3
(en)
|
2003-10-16 |
2009-12-09 |
Imclone LLC |
Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
|
|
CA2541651C
(en)
|
2003-10-22 |
2011-05-24 |
Keck Graduate Institute |
Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
|
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
|
WO2005053742A1
(ja)
|
2003-12-04 |
2005-06-16 |
Kyowa Hakko Kogyo Co., Ltd. |
抗体組成物を含有する医薬
|
|
EP1697420A2
(en)
|
2003-12-19 |
2006-09-06 |
Five Prime Therapeutics, Inc. |
Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
|
|
EP1740615B1
(en)
|
2004-03-31 |
2014-11-05 |
Genentech, Inc. |
Humanized anti-tgf-beta antibodies
|
|
WO2005115363A2
(en)
|
2004-05-25 |
2005-12-08 |
Yale University |
Method for treating skeletal disorders resulting from fgfr malfunction
|
|
WO2006076288A2
(en)
|
2005-01-11 |
2006-07-20 |
Five Prime Therapeutics, Inc. |
Dna constructs for long-term expression of intravascularly injected naked dna
|
|
US7923538B2
(en)
|
2005-07-22 |
2011-04-12 |
Kyowa Hakko Kirin Co., Ltd |
Recombinant antibody composition
|
|
CA2648021A1
(en)
|
2006-03-31 |
2007-10-11 |
Ordway Research Institute, Inc. |
Prognostic and diagnostic method for cancer therapy
|
|
JP2009536834A
(ja)
|
2006-05-12 |
2009-10-22 |
ジェネンテック・インコーポレーテッド |
癌の診断及び治療のための方法及び組成物
|
|
WO2007146847A2
(en)
|
2006-06-09 |
2007-12-21 |
University Of Maryland, Baltimore |
Glycosylation engineered antibody therapy
|
|
US8101721B2
(en)
|
2006-06-15 |
2012-01-24 |
Fibron Ltd. |
Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
|
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
|
DK2066694T3
(en)
|
2006-09-29 |
2016-02-08 |
Oncomed Pharm Inc |
Compositions and Methods for Diagnosing and Treating Cancer
|
|
EP2094733A1
(en)
|
2006-11-03 |
2009-09-02 |
U3 Pharma GmbH |
Fgfr4 antibodies
|
|
AR063975A1
(es)
|
2006-11-28 |
2009-03-04 |
Centelion |
Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
|
|
AR064464A1
(es)
|
2006-12-22 |
2009-04-01 |
Genentech Inc |
Anticuerpos anti - receptor del factor de crecimiento insulinico
|
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
|
AU2008208288B2
(en)
|
2007-01-24 |
2014-04-03 |
Kyowa Kirin Co., Ltd. |
Genetically recombinant antibody composition having enhanced effector activity
|
|
CA2680046A1
(en)
|
2007-03-23 |
2008-10-02 |
The Translational Genomics Research Institute |
Methods of diagnosing, classifying and treating endometrial cancer and precancer
|
|
CA2682382A1
(en)
|
2007-03-28 |
2008-10-09 |
Biogen Idec Inc. |
Non-fucosylated antibodies
|
|
EP2205277B1
(en)
|
2007-10-22 |
2017-07-26 |
Genmab A/S |
Novel antibody therapies
|
|
WO2009100105A2
(en)
|
2008-02-04 |
2009-08-13 |
Attogen Inc. |
Inhibitors of oncogenic isoforms and uses thereof
|
|
US9260525B2
(en)
|
2008-02-04 |
2016-02-16 |
Xiao-Jia Chang |
Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
|
|
WO2009151448A1
(en)
|
2008-06-10 |
2009-12-17 |
University Of Southern California |
Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
HUE035700T2
(en)
|
2008-11-07 |
2018-05-28 |
Galaxy Biotech Llc |
Monoclonal antibodies to Fibroblast Growth Factor receptor 2
|
|
US20120301482A1
(en)
|
2009-08-25 |
2012-11-29 |
National Jewish Health |
Methods and compositions for treatment of lung injury
|
|
CA2777068C
(en)
|
2009-10-14 |
2020-05-26 |
Humanigen, Inc. |
Antibodies to epha3
|
|
RU2012134637A
(ru)
|
2010-01-14 |
2014-02-20 |
Йейл Юниверсити |
Ингибиторы рецепторных тирозинкиназ (rtk) и способы их применения
|
|
US9140689B2
(en)
|
2010-03-14 |
2015-09-22 |
Translational Genomics Research Institute |
Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
|
|
RU2012153241A
(ru)
|
2010-05-11 |
2014-06-20 |
Авео Фармасьютикалз, Инк. |
Антитела к fgfr2
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
EP2603521A4
(en)
|
2010-08-12 |
2014-10-01 |
Attogen Inc |
ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES
|
|
US20120258496A1
(en)
|
2010-09-27 |
2012-10-11 |
Boehringer Ingelheim International Gmbh |
Production of low fucose antibodies in h4-ii-e rat cells
|
|
EP3828205A1
(en)
|
2010-10-01 |
2021-06-02 |
Oxford BioTherapeutics Ltd |
Anti-ror1 antibodies
|
|
EP2714738B1
(en)
*
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
AR088941A1
(es)
|
2011-11-23 |
2014-07-16 |
Bayer Ip Gmbh |
Anticuerpos anti-fgfr2 y sus usos
|
|
SG11201403085PA
(en)
|
2011-12-14 |
2014-10-30 |
Seattle Genetics Inc |
Fgfr antibody drug conjugates (adcs) and the use thereof
|
|
WO2013148263A1
(en)
|
2012-03-30 |
2013-10-03 |
The Regents Of The University Of California |
Anti-emp2 therapy reduces cancer stem cells
|
|
AU2013247645B2
(en)
|
2012-04-09 |
2019-02-14 |
Daiichi Sankyo Company, Limited |
Anti-FGFR2 antibody
|
|
US9254288B2
(en)
|
2012-05-07 |
2016-02-09 |
The Translational Genomics Research Institute |
Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
|
|
HK1203971A1
(en)
|
2012-05-15 |
2015-11-06 |
Bristol-Myers Squibb Company |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
|
US20150191791A1
(en)
|
2012-07-05 |
2015-07-09 |
Lsip, Llc |
Fgfr2 fusion gene
|
|
WO2014089193A1
(en)
|
2012-12-04 |
2014-06-12 |
Aveo Pharmaceuticals, Inc. |
Anti-fgfr2 antibodies
|
|
CA3150658A1
(en)
|
2013-01-18 |
2014-07-24 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
US9415118B2
(en)
|
2013-03-13 |
2016-08-16 |
Novartis Ag |
Antibody drug conjugates
|
|
US20160067307A1
(en)
|
2013-05-01 |
2016-03-10 |
Five Prime Therapeutics, Inc. |
Methods of treating cancer
|
|
US20160130661A1
(en)
|
2013-06-13 |
2016-05-12 |
University Of South Australia |
Methods for detecting prostate cancer
|
|
KR102516152B1
(ko)
|
2013-08-01 |
2023-03-31 |
파이브 프라임 테라퓨틱스, 인크. |
비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
WO2015116868A2
(en)
|
2014-01-29 |
2015-08-06 |
Caris Mpi, Inc. |
Molecular profiling of immune modulators
|
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
US10478494B2
(en)
|
2015-04-03 |
2019-11-19 |
Astex Therapeutics Ltd |
FGFR/PD-1 combination therapy for the treatment of cancer
|
|
MX2018006181A
(es)
|
2015-11-23 |
2018-09-24 |
Five Prime Therapeutics Inc |
Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
|
|
PT3624837T
(pt)
|
2017-05-16 |
2025-10-01 |
Five Prime Therapeutics Inc |
Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro
|